siRNA-Mediated Silencing of CIP2A Enhances Docetaxel Activity Against PC-3 Prostate Cancer Cells

Saiedeh Razi Soofiyani ^1,2, Akbar Mohammad Hoseini ¹, Ali Mohammadi ¹, Vahid Khaze Shahgoli ¹, Behzad Baradaran ¹ * , Mohammad Saeid Hejazi ^3,2 *

Cited by CrossRef: 10

1- Yuan S, Qiao T, Qiang J. Diffusion-weighted imaging and diffusion kurtosis imaging for early evaluation of the response to docetaxel in rat epithelial ovarian cancer. J Transl Med. 2018;16(1) [Crossref]

2- Manivannan S, Nagaraj S, Narayan S. A Reflection on the Mechanism of the Role of Nanoparticles in Increasing the Efficacy of Anti-tumour Properties of Docetaxel. Curr Pathobiol Rep. 2021;9(3):79 [Crossref]

3- Baghbani E, Khaze V, Sadreddini S, Mokhtarzadeh A, Mansoori B, Mohammadi A, Vatankhahan V, Toosi P, Baradaran B. PTPN22 Silencing in Human Acute T-Cell Leukemia Cell Line (Jurkat Cell) and its Effect on the Expression of miR-181a and miR-181b. Adv Pharm Bull. 2018;8(2):277 [Crossref]

4- Mirzaei S, Gholami M, Hashemi F, Zabolian A, Hushmandi K, Rahmanian V, Entezari M, Girish Y, Sharath Kumar K, Aref A, Makvandi P, Ashrafizadeh M, Zarrabi A, Khan H. Employing siRNA tool and its delivery platforms in suppressing cisplatin resistance: Approaching to a new era of cancer chemotherapy. Life Sciences. 2021;277:119430 [Crossref]

5- Chen W, Liang J, Zhou K, Zeng Q, Ye J, Huang M. Effect of CIP2A and its mechanism of action in the malignant biological behavior of colorectal cancer. Cell Commun Signal. 2020;18(1) [Crossref]

6- Wang N, Zhou F, Guo J, Zhu H, Luo S, Cao J. RETRACTED: Euxanthone suppresses tumor growth and metastasis in colorectal cancer via targeting CIP2A/PP2A pathway. Life Sciences. 2018;209:498 [Crossref]

7- Ashrafizadeh M, Hushmandi K, Rahmani Moghadam E, Zarrin V, Hosseinzadeh Kashani S, Bokaie S, Najafi M, Tavakol S, Mohammadinejad R, Nabavi N, Hsieh C, Zarepour A, Zare E, Zarrabi A, Makvandi P. Progress in Delivery of siRNA-Based Therapeutics Employing Nano-Vehicles for Treatment of Prostate Cancer. Bioengineering. 2020;7(3):91 [Crossref]

8- Bahreyni A, Luo H. Advances in Targeting Cancer-Associated Genes by Designed siRNA in Prostate Cancer. Cancers. 2020;12(12):3619 [Crossref]

9- Ashrafizadeh M, Zarrabi A, Hushmandi K, Hashemi F, Rahmani Moghadam E, Raei M, Kalantari M, Tavakol S, Mohammadinejad R, Najafi M, Tay F, Makvandi P. Progress in Natural Compounds/siRNA Co-delivery Employing Nanovehicles for Cancer Therapy. ACS Comb Sci. 2020;22(12):669 [Crossref]

10- Chen W, Yi H, Chen X, Xie W, Tang X, Ye J, Peng X, Zhang Y, Liang J, Huang M. Prognostic value of the NLR combined with CIP2A in the serum of patients with colorectal cancer. BMC Surg. 2021;21(1) [Crossref]